Lipocine announces multiple poster presentations at the american association for the study of liver diseases (aasld) the liver meeting® 2021

Salt lake city, nov. 1, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that three abstracts have been selected for poster presentations during the upcoming the liver meeting® 2021, organized by the american association for the study of liver diseases (aasld) to take place november 12-15, 2021. presentation details: session title: late-breaking abstract posters publication number:      lp46 poster title:                  "lpcn 1144 therapy demonstrates histologic benefits in the phase 2 lift study in non-alcoholic steatohepatitis (nash) subjects" session title:             late-breaking abstract posters publication number:     lp47 poster title:                    "safety and tolerability of lpcn 1144 treatment in biopsy confirmed nash subjects in the phase 2 lift study" session title:                  nafld and nash: experimental: clinical publication number:      1876 poster title:                   "lpcn 1144 improves body composition in biopsy-confirmed nash patients" the abstracts will be available for viewing by attendees of the liver meeting® 2021 on the aasld website and the online planner of the liver meeting® app november 1, 2021 at 10:00 am et and will be published in the december issue of hepatology.
LPCN Ratings Summary
LPCN Quant Ranking